Pfizer licenses Protalix's Gaucher's disease product; Genzyme resumes Cerezyme shipments
This article was originally published in Scrip
Executive Summary
Pfizer is to pay Protalix $60 million up front to license the latter's plant enzyme-derived Gaucher's disease therapy, taliglucerase alfa. It will pay a further $55 million in regulatory milestones for the product, which is already being provided to patients in the US under an expanded access program (EAP) treatment protocol and in the EU under a compassionate use protocol.